491 related articles for article (PubMed ID: 17200271)
1. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates.
Ferreira E; Carceller AM; Agogué C; Martin BZ; St-André M; Francoeur D; Bérard A
Pediatrics; 2007 Jan; 119(1):52-9. PubMed ID: 17200271
[TBL] [Abstract][Full Text] [Related]
2. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.
Nulman I; Koren G; Rovet J; Barrera M; Pulver A; Streiner D; Feldman B
Am J Psychiatry; 2012 Nov; 169(11):1165-74. PubMed ID: 23128923
[TBL] [Abstract][Full Text] [Related]
3. [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].
de Moor RA; Mourad L; ter Haar J; Egberts AC
Ned Tijdschr Geneeskd; 2003 Jul; 147(28):1370-2. PubMed ID: 12892015
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
Oberlander TF; Misri S; Fitzgerald CE; Kostaras X; Rurak D; Riggs W
J Clin Psychiatry; 2004 Feb; 65(2):230-7. PubMed ID: 15003078
[TBL] [Abstract][Full Text] [Related]
5. Prenatal exposure to antidepressants: how safe are they?
Steiner M
Am J Psychiatry; 2012 Nov; 169(11):1130-2. PubMed ID: 23128917
[No Abstract] [Full Text] [Related]
6. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants.
Augustin BG; Cold JA; Jann MW
Pharmacotherapy; 1997; 17(3):511-30. PubMed ID: 9165554
[TBL] [Abstract][Full Text] [Related]
7. Venlafaxine: a 2003 update.
Gutierrez MA; Stimmel GL; Aiso JY
Clin Ther; 2003 Aug; 25(8):2138-54. PubMed ID: 14512125
[TBL] [Abstract][Full Text] [Related]
8. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.
Furu K; Kieler H; Haglund B; Engeland A; Selmer R; Stephansson O; Valdimarsdottir UA; Zoega H; Artama M; Gissler M; Malm H; Nørgaard M
BMJ; 2015 Apr; 350():h1798. PubMed ID: 25888213
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
[TBL] [Abstract][Full Text] [Related]
10. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.
Moses-Kolko EL; Bogen D; Perel J; Bregar A; Uhl K; Levin B; Wisner KL
JAMA; 2005 May; 293(19):2372-83. PubMed ID: 15900008
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of the new antidepressants.
Nelson JC
J Clin Psychiatry; 1997; 58 Suppl 6():26-31. PubMed ID: 9227670
[TBL] [Abstract][Full Text] [Related]
12. Neonatal Discontinuation Syndrome in Serotonergic Antidepressant-Exposed Neonates.
Yang A; Ciolino JD; Pinheiro E; Rasmussen-Torvik LJ; Sit DKY; Wisner KL
J Clin Psychiatry; 2017 May; 78(5):605-611. PubMed ID: 28570796
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant options: venlafaxine in perspective.
Thase ME
J Clin Psychopharmacol; 1996 Jun; 16(3 Suppl 2):10S-18S; discussion 18S-20S. PubMed ID: 8784644
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study.
Einarson A; Fatoye B; Sarkar M; Lavigne SV; Brochu J; Chambers C; Mastroiacovo P; Addis A; Matsui D; Schuler L; Einarson TR; Koren G
Am J Psychiatry; 2001 Oct; 158(10):1728-30. PubMed ID: 11579012
[TBL] [Abstract][Full Text] [Related]
15. Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose.
Roca A; Garcia-Esteve L; Imaz ML; Torres A; Hernández S; Botet F; Gelabert E; Subirà S; Plaza A; Valdés M; Martin-Santos R
J Affect Disord; 2011 Dec; 135(1-3):208-15. PubMed ID: 21890210
[TBL] [Abstract][Full Text] [Related]
16. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy.
Boucher N; Bairam A; Beaulac-Baillargeon L
J Clin Psychopharmacol; 2008 Jun; 28(3):334-9. PubMed ID: 18480693
[TBL] [Abstract][Full Text] [Related]
17. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.
Khan A; Upton GV; Rudolph RL; Entsuah R; Leventer SM
J Clin Psychopharmacol; 1998 Feb; 18(1):19-25. PubMed ID: 9472838
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine: not yet first in the antidepressant class.
Harv Ment Health Lett; 2003 Apr; 19(10):5-7. PubMed ID: 12711568
[No Abstract] [Full Text] [Related]
19. Hyponatraemia in elderly psychiatric patients treated with Selective Serotonin Reuptake Inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit.
Kirby D; Harrigan S; Ames D
Int J Geriatr Psychiatry; 2002 Mar; 17(3):231-7. PubMed ID: 11921151
[TBL] [Abstract][Full Text] [Related]
20. [Neonatal outcome after exposure to selective serotonin reuptake inhibitors late in pregnancy].
Cissoko H; Swortfiguer D; Giraudeau B; Jonville-Béra AP; Autret-Leca E
Arch Pediatr; 2005 Jul; 12(7):1081-4. PubMed ID: 15964522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
